SMART与按需治疗在轻至重度哮喘中的网络荟萃分析
在成人轻中度哮喘中,低剂量SMART和按需低剂量ICS/LABA组合在降低急性加重风险上显著优于其他按需治疗,且均排名第一。在成人中重度哮喘中,低至中剂量SMART与高剂量ICS/LABA+按需SABA在降低重度急性加重风险上疗效相当,但仅低至中剂量SMART排名第一。
要点
- 成人轻中度哮喘:低剂量SMART和按需低剂量ICS/LABA降低急性加重风险显著优于其他按需治疗。
- 成人中重度哮喘:低至中剂量SMART与高剂量ICS/LABA+按需SABA降低重度急性加重风险疗效相当。
- 上述治疗总体耐受良好,对肺功能和疾病控制也有效。
核心结论
- 本研究支持SMART和按需治疗作为哮喘的合适治疗选择,并根据疾病严重程度提供了每种特定治疗的最有效定位。
主要发现
- 在成人轻中度哮喘患者中,低剂量SMART和按需低剂量ICS/LABA组合在降低急性加重风险方面显著更有效(相对效应<0.78;p<0.05),且两者均排名第一,达到SUCRA第一四分位。
- 在成人中重度哮喘患者中,低至中剂量SMART与高剂量ICS/LABA+按需SABA在降低重度哮喘急性加重风险方面疗效相当(p>0.05),但仅低至中剂量SMART排名第一(SUCRA第一四分位)。
- 总体而言,这些治疗耐受良好,对肺功能和疾病控制也有效。
临床怎么用
- 临床可根据哮喘严重程度选择SMART或按需治疗:轻中度可考虑低剂量SMART或按需低剂量ICS/LABA,中重度可考虑低至中剂量SMART。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, there are no network meta-analyses comparing the impact of as-needed treatments in asthma, including the single maintenance and reliever therapy (known as "SMART" or "MART"; for simplicity, SMART will be used hereafter) and the use of inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination exclusively on an as-needed basis. Therefore, we performed a systematic review and network meta-analysis concerning the efficacy and safety of SMART and as-needed therapies in asthma. Data from 32 096 asthmatic patients were extracted from 21 studies, lasting from 6 to 12 months. In adult mild-to-moderate asthmatic patients low-dose SMART and as-needed low-dose ICS/LABA combination were significantly (relative effect <0.78; p<0.05) more effective than the other as-needed therapies in reducing the risk of exacerbation, and both were ranked as the first treatment option reaching the first quartile of the surface under the cumulative ranking curve analysis (SUCRA). In adult moderate-to-severe asthmatic patients, low-dose to medium-dose SMART and high-dose ICS/LABA+as-needed short-acting β2-agonist were equally effective in reducing the risk of severe asthma exacerbation (p>0.05), although only low- to medium-dose SMART was ranked as the first treatment option (first SUCRA quartile). Overall, these treatments were well tolerated, and effective also on lung function and disease control. This study supports SMART and as-needed therapies as a suitable therapeutic option for asthma, by providing the most effective positioning of each specific treatment according to the disease severity.
引用
- Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020. PMID: 32430423. doi:10.1183/13993003.00625-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。